ORYZON to Provide Corporate Progress Updates at Several Events in November

  • BIO-Europe 2023
  • LSX Investival Showcase 2023
  • Jefferies London Healthcare Conference 2023

MADRID, Spain and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in November.

Oryzon will participate in the BIO-Europe 2023 conference, which will be held on November 6-8 at the Trade Fair Center Messe München in Munich (Germany), and virtually on November 14-15. The company will hold one-on-one meetings with pharmaceutical companies and global investors. Click on link for more info about BIO-Europe 2023

Oryzon's CEO, Dr. Carlos Buesa, will attend the LSX Investival Showcase, to be held on November 13 at at Old Billingsgate in London (UK). Click on link for more info about the LSX Investival Showcase 2023

The Company has been invited to attend and present the company at the Jefferies London Healthcare Conference, to be held at the Waldorf Hilton in London on November 14-16, where the company will also hold one-on-one meetings with global investors. Click on link for more info about Jefferies 2023 London Healthcare Conference

About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon's team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS and iadademstat in oncology, in several Phase II clinical trials. The company has other pipeline assets directed against other epigenetic targets. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit

About Iadademstat
Iadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers (see Maes et al., Cancer Cell 2018 Mar 12; 33 (3): 495-511.e12.doi: 10.1016 / j.ccell.2018.02.002.). A FiM Phase I/IIa clinical trial with iadademstat in R/R AML patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi (see Salamero et al, J Clin Oncol, 2020, 38(36): 4260-4273. doi: 10.1200/JCO.19.03250). In a recently completed Phase IIa trial in elder 1L-AML patients (ALICE trial), iadademstat has shown encouraging safety and efficacy ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner